DNJ-20

DNJ-20 is an α-glucosidase inhibitor (IC50: 55.3 μg/mL) . DNJ-20 has broad-spectrum anti-SARS-CoV-2 activity. DNJ-20 inhibits the correct processing of viral glycoproteins by interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), thereby blocking the formation and infection of viral particles. DNJ-20 has IC50 values up to 1.49 uM against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43。DNJ-20 can be used for pan-coronavirus research[1].

Product Specifications

CAS Number

[3081926-49-7]

UNSPSC

12352005

Target

Glycosidase; SARS-CoV

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Field of Research

Infection; Inflammation/Immunology

Smiles

O=C1C=C(C2=CC=C(O)C(O)=C2)OC3=C1C(OCCCCCCCCCCN4[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C4)=CC(O)=C3

Molecular Formula

C31H41NO10

Molecular Weight

587.66

References & Citations

[1]Liu YY, et al. TCM theory-inspired discovery of DNJ-flavonoid conjugates as broad-spectrum anti-SARS-CoV-2 agents by primarily targeting ER-associated glycoprotein folding process. Eur J Med Chem. 2025 Jun 5;290:117582.